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Research Article
Associations Between Components of Metabolic
Syndrome and Cognition in Patients With Schizophrenia
The metabolic syndrome and cognitive dys-
functions are common in patients with schizo-
phrenia, yet there is no general consensus con-
cerning the effects of the components of the
metabolic syndrome on various cognitive
domains. The goal of this study was to inves-
tigate the relationship between components of
the metabolic syndrome and cognition in
patients with schizophrenia. Components of the
metabolic syndrome and neurocognitive func-
tioning were assessed in 68 patients with schiz-
ophrenia. The Brief Assessment of Cognition in
Schizophrenia (BACS) was used to assess neu-
rocognition. Hyperglycemia and hypertension
were the only components of the metabolic
syndrome found to be associated with cognitive
functioning. Patients with schizophrenia who
were hypertensive showed cognitive impair-
ments in 2 domains, with a negative association
found between hypertension and verbal mem-
ory (P=0.047) and verbal ﬂuency (P=0.007).
Hyperglycemia was associated with higher
scores on verbal memory (P=0.01) and verbal
ﬂuency (P<0.001). It appears that medical
treatment of certain components of the meta-
bolic syndrome could affect cognitive perform-
ance in patients with schizophrenia.
(Journal of Psychiatric Practice 2015;21;
190–197)
KEY WORDS: metabolic syndrome, schizophrenia,
cognition, hypertension, hyperglycemia
The metabolic syndrome and its components,
including abdominal obesity, dyslipidemia, hyper-
glycemia, and hypertension, are very prevalent in
patients with schizophrenia.1,2 The prevalence of
the metabolic syndrome in patients with schizo-
phrenia in the United States and Canada has been
reported as 43% and 46%, respectively.1,3 Genetic
risk factors, increased cortisol level, unhealthy diet,
lack of exercise, and antipsychotic treatment are
factors that contribute to the etiology of the meta-
bolic syndrome in schizophrenia.4–6
The performances of patients with schizophrenia
are 1.5 to 2.0 SDs below healthy controls on a range of
neurocognitive tasks, including verbal memory, ver-
bal ﬂuency, working memory, motor speed, attention,
and executive function.7 Studies have also shown that
cognitive deﬁcits may be a cause of poor social and
occupational functioning.8,9 Consequently, cognitive
deﬁcits have become a potential pharmacological
target to improve quality of life and functional
capacity in patients with schizophrenia.7,10
Recently, attention has focused on the effects of
the metabolic syndrome on cognitive functioning.
Some studies have shown that the metabolic syn-
drome and its components may lead to poorer cog-
nitive functioning in the general population.11
However, a recent study challenged the notion that
the metabolic syndrome and its components have a
negative effect on cognition.12 Those researchers
found that elderly participants with metabolic
syndrome had better cognitive functions than those
without metabolic syndrome.
A few studies have investigated the effects of the
components of metabolic syndrome on cognitive
domains in schizophrenia, but the results have been
contradictory.13–18 Although 1 study demonstrated
that patients with schizophrenia, hypertension, and
increased body mass index had more cognitive def-
icits than the control group,15 other studies found a
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relationship only between hyperglycemia, but not
hypertension or abdominal obesity, and cognitive
impairments in schizophrenia.14,16 Another study
reported that high levels of triglycerides, abdominal
obesity, and low levels of high-density lipoprotein
(HDL) cholesterol were the only metabolic factors
that were associated with memory impairment in
schizophrenia.17 The Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE) study failed
to ﬁnd any association between metabolic syndrome
and cognitive domains.18 One explanation for these
negative results in the CATIE study may be that
the patients were divided into 2 groups, those who
met and those who did not meet any 3 of the 5 cri-
teria for the metabolic syndrome. This dichoto-
mization may have masked the effects of individual
components of the metabolic syndrome on cognition.
The study described here was designed to exam-
ine the association between the individual compo-
nents of the metabolic syndrome and cognitive
dysfunctions in patients with schizophrenia. To
assess various cognitive domains, the Brief
Assessment of Cognition in Schizophrenia (BACS)
was used.19,20 The BACS was speciﬁcally designed
to assess cognitive function in schizophrenia, and
time required to administer (approximately 35min)
and score it is brief. Studies have shown acceptable
reliability and concurrent validity of the BACS with
a standard cognitive battery.19,20
METHODS
Participants
A convenience sample of 68 patients with schizo-
phrenia (46 male and 22 female patients) was
recruited over a period of approximately 3 months. All
of the patients had been receiving treatment as inpa-
tients for at least 2 years in the psychiatry clinic at the
Golestan Mental Health Hospital. In this sample, the
average age was 42.4 years (SD 9.5y), the average
educational level completed was 10.1 years (SD 5.2 y),
and the average duration of illness was 16.3 years (SD
8.1 y). Patients enrolled in the study were receiving
antipsychotic medication and were clinically stable.
The inclusion criteria included: (1) age 18 to 65 years;
(2) DSM-IV21 diagnosis of schizophrenia (all subtypes)
or schizoaffective disorder with illness duration
≥2 years; (3) auditory and visual acuity adequate to
complete the cognitive tests; (5) stable dose of primary
typical or atypical antipsychotic for at least 4 weeks;
(6) no physical health problem requiring frequent
changes in medications; and (7) capacity and willing-
ness to give written informed consent. Exclusion cri-
teria included: (1) inability to read or speak; (2)
documented disease of the central nervous system; (3)
intellectual disability; (4) a clinically signiﬁcant or
unstable cardiovascular, renal, hepatic, gastro-
intestinal, pulmonary, or hematological condition; (5)
a medical problem that might affect cognition (eg,
human immunodeﬁciency virus infection, an episode
of anoxia, head injury, cerebrovascular accident, Par-
kinson disease, Alzheimer disease, seizure disorders);
and (6) a diagnosis of substance dependence.21 All
patients gave informed consent and were adminis-
tered a set of comprehensive fasting metabolic meas-
ures and a set of neurocognitive measures (BACS)
during the baseline period of the study. The study was
approved by the Ethics Committees of Kerman Uni-
versity of Medical Sciences.
Measures
Assessment of Metabolic Syndrome
The components of the metabolic syndrome were
deﬁned according to the National Cholesterol Edu-
cation Program–Adult Treatment Panel III criteria
(NCEP-ATPIII),22 as follows:
 Central obesity: waist circumference ≥102 cm or
40 inches (male) or ≥88 cm or 36 inches (female).
 Dyslipidemia: triglyceride level ≥1.7mmol/L
(150mg/dL).
 Dyslipidemia: HDL-C<40mg/dL (male) or <50
mg/dL (female).
 Blood pressure ≥130/85mm Hg.
 Fasting plasma glucose ≥5.6mmol/L (100mg/
dL).
In addition, patients receiving antidiabetic
agents, antihypertensive agents, or speciﬁc treat-
ment for dyslipidemia were generally considered as
meeting the component criterion for glucose, blood
pressure, or triglycerides/HDL, respectively.
Waist circumference was measured at the mid-
point between the lower rib margins and the iliac
crest. Arterial blood pressure was recorded using a
standard mercury sphygmomanometer. Using
standard enzymatic techniques, a comprehensive
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battery of metabolic measures was assessed at
baseline, including fasting blood samples (drawn
fasting between 6:00 and 8:00 AM) for glucose, total
cholesterol, total triglycerides, HDL, and low-den-
sity lipoprotein levels. Chlorpromazine equivalent
doses were also calculated for each patient.23
Assessment of Cognitive Function
Neurocognitive assessments were performed by
trained physicians who were unaware of the study
hypothesis. All of the participants were tested using
the Persian version of the BACS, which has been
validated in a sample of patients with schizophrenia
who spoke Persian.24 The battery of tests in the BACS
includes brief assessments of verbal memory, working
memory, motor speed, verbal ﬂuency, reasoning and
problem-solving, and attention.
List Learning (verbal memory): Patients were
presented with 15 words and then asked to recall as
many as possible. This procedure was repeated 5
times.
Digit Sequencing Task (working memory):
Patients were presented with clusters of numbers of
increasing length. They were asked to tell the
experimenter the numbers in order, from lowest to
highest.
Token Motor Task (motor speed): Patients were
given 100 plastic tokens and asked to place them
into a container as quickly as possible for 60
seconds.
Verbal Fluency: Patients were given 60 seconds to
name as many words as possible within a given
category (semantic ﬂuency). Also, in 2 separate tri-
als, patients were given 60 seconds to generate as
many words as possible beginning with a certain
letter (letter ﬂuency). The total number of words
from the 3 trials was the outcome measure.
Tower of London (reasoning and problem-solv-
ing): Patients looked at 2 pictures simultaneously.
Each picture showed 3 balls of different colors
arranged on 3 pegs, with the balls in a unique
arrangement in each picture. The patients were told
about the rules in the task and were asked to pro-
vide the least number of times the balls in one
picture would have to be moved to make the
arrangement of balls identical to that of the other
picture.
Symbol Coding (attention and processing speed):
Patients received a key explaining how unique
symbols correspond to the individual numerals 1 to
9. They were asked to ﬁll in the corresponding
number beneath a series of symbols as quickly as
possible for 90 seconds.
Statistical Analysis
χ2 and t tests were applied to analyze the demo-
graphic and clinical data. To examine the relation-
ship between the components of the metabolic
syndrome and cognitive domains (as outcome vari-
ables), multivariate linear regression was used. P
values <0.05 were considered signiﬁcant. IBM
SPSS 21 software was used for the statistical
analyses.
RESULTS
Table 1 summarizes the demographic and clinical
characteristics of all patients using the individual
components of the metabolic syndrome. The preva-
lence rate for individual components of the meta-
bolic syndrome in this sample was 20.6% for
hyperglycemia, 23.5% for hypertension, 47.1% for
low HDL cholesterol, 64.7% for high triglycerides,
and 54.4% for abdominal obesity. Seventeen of the
46 men (37%) were current smokers; however, none
of them was allowed to smoke >5 cigarettes per day.
Twelve of the 16 patients with hypertension (75%)
were on antihypertensive treatments (ie, metopro-
lol, nitrates, losartan, or propranolol). Seven of these
patients with hypertension (44%) were receiving
ﬁrst-generation antipsychotics, and 13 (81%) were
receiving second-generation antipsychotics (some
patients were receiving >1 type of antipsychotic).
Eight of the 14 patients with hyperglycemia (57%)
were on oral antihyperglycemic agents (ie, glyburide
or metformin). None of the patients was receiving
insulin therapy. Five of the patients with hyper-
glycemia (36%) were receiving ﬁrst-generation
antipsychotics, and 12 (86%) were receiving second-
generation antipsychotics (some patients were
receiving >1 type of antipsychotic).
The results of the multivariate analyses are
shown in Table 2. Our models were all adjusted for
sex, age, educational levels, duration of disease, and
chlorpromazine dose equivalents. After these
adjustments, the diagnosis of hypertension pre-
dicted a poorer score on the cognitive domains of
verbal memory (P= 0.047) and verbal ﬂuency
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(P= 0.007), whereas the diagnosis of hyperglycemia
predicted better scores on the cognitive domains of
verbal memory (P=0.01) and verbal ﬂuency
(P<0.001). Other aspects of the metabolic syndrome
(ie, waist circumference and dyslipidemia) were
not signiﬁcant predictors for any of the individual
cognitive domains (Table 2). The model was not
ﬁtted for working memory (P= 0.11), motor speed
(P= 0.28), and reasoning and problem-solving
(P= 0.08). There was a signiﬁcant relationship
between poorer cognitive performance and lower
levels of education and higher antipsychotic doses
(P<0.05).
DISCUSSION
This study investigated the association between the
components of the metabolic syndrome (hyper-
glycemia, dyslipidemia, hypertension, and abdomi-
nal obesity) and cognitive functioning in patients
with schizophrenia. Our ﬁndings provided evidence
for a correlation between hypertension and cogni-
tive impairments in schizophrenia. Interestingly,
the patients with schizophrenia and hyperglycemia
showed signiﬁcantly better cognitive functioning
than the patients without hyperglycemia. We did
not ﬁnd any signiﬁcant association between other
components of metabolic syndrome and cognitive
performance. Higher levels of education and lower
antipsychotic doses, which may be representative of
less severe psychosis, were also associated with
better cognitive functioning.
The prevalence of metabolic syndrome in our
patients was 48.5% (n=33), which is consistent
with another study from Iran, which found a 40%
prevalence of metabolic syndrome in patients with
schizophrenia.25 Moreover, our ﬁnding is consistent
with reports from Western countries. For example,
the prevalence of metabolic syndrome in patients
with schizophrenia has been reported to be 43% and
46% in the United States and Canada, respec-
tively.1,3 The prevalence of the metabolic syndrome
in the general population of Iran has been reported
to range from 22.8% to >30% according to different
studies.26–28
In this study, patients with schizophrenia and
comorbid hypertension showed more deﬁcits in the
cognitive domains of verbal memory and verbal
ﬂuency than nonhypertensive patients with schiz-
ophrenia. Most of these patients (75%) were beingT
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treated with antihypertensive agents. This ﬁnding
is consistent with that of Friedman et al,15 who
reported in 2010 that hypertension had a negative
impact on verbal memory in patients with schizo-
phrenia being treated with antihypertensive medi-
cations. Our ﬁndings are also consistent with the
results of nonpsychiatric studies that have similarly
shown impaired verbal memory in hypertensive
patients receiving antihypertensive treatment.29
However, some studies have failed to show any
association between high blood pressure and cog-
nitive functioning in schizophrenia.14,17,30 This dis-
crepancy may be explained by variations in the
populations and methodology used in these studies
[eg, different cutoff points for hypertension (130mm
Hg in our study vs. 140mm Hg), different races
(white vs. Hispanic vs. African American), and dif-
ferent neurocognitive batteries used to assess the
cognitive domains]. It is also important to note that
these studies did not adjust their results for the
duration of illness, lifestyle, diet, and dose of anti-
psychotic medications. All of these factors may
affect assessments of both the components of the
metabolic syndrome and cognitive functioning.31–35
In our study, however, all participants had a rela-
tively similar lifestyle, leisure activities, and diet as
they were living in the same care center for chronic
mental disorders. Finally, it has been suggested
that different types of antihypertensive medications
may have varying effects on cognitive function. For
example, blockade of the renin-angiotensin system
may prevent cognitive decline in hypertensive
patients.36–39
Our results demonstrated that patients with
schizophrenia who were hyperglycemic but not
necessarily diabetic performed signiﬁcantly better
on verbal memory and verbal ﬂuency than those
without hyperglycemia. This ﬁnding is partially
consistent with the results of the CATIE study,13 in
which it was found that diabetes had a negative
effect on all cognitive domains except verbal mem-
ory and working memory in patients with schizo-
phrenia. It should be mentioned that the cutoff
point for hyperglycemia in our study was 100mg/
dL, whereas it was 126mg/dL in the CATIE
study. Among hyperglycemic patients in our study,
35.7% had fasting blood glucose <126, which may
explain this discrepancy. However, our results are
inconsistent with several other studies.14,16,17 For
example, in a study published in 2008, Dickinson
and colleagues compared cognitive performance in 3
groups: patients with schizophrenia and comorbid
diabetes, patients with schizophrenia without dia-
betes, and diabetic patients. Their results showed
more cognitive impairment in the patients with
schizophrenia and comorbid diabetes than in the
other 2 groups, especially in the domains of proc-
essing speed and visual/spatial ability.16 These
discrepancies in results may be due to method-
ological and population differences in the studies,
such as the different cutoff points for hyperglycemia
and the duration of hyperglycemia. In particular,
studies have shown that the duration of diabetes or
hyperglycemia is related to cognitive function-
ing.40,41 Future studies are needed to assess the
effect of duration of diabetes on cognitive function in
schizophrenia.
Our study failed to show any association between
abdominal obesity or dyslipidemia and cognitive
functioning. These results are consistent with a
study that involved 1289 patients with schizo-
phrenia and found no relationship between
abdominal obesity or dyslipidemia and cognitive
functioning.13 However, 2 other studies found an
association between abdominal obesity and cogni-
tive deﬁcits in patients with schizophrenia.14,30 In a
study published in 2012, Lindenmayer et al14 found
that greater waist circumference, lower HDL, and
higher triglycerides were associated with impaired
attention/vigilance. In a study published in 2013,
Boyer et al30 found a relationship between
abdominal obesity and poor processing speed, and
between hypertriglyceridemia and poor attention/
vigilance, executive functioning, verbal memory,
and processing speed. The explanation for the dif-
ferent results could be the duration of the metabolic
syndrome, the ethnicity of the populations studied
(mainly African American in the study by Linden-
mayer and colleagues), and/or the mean age (rela-
tively young average age in the study by Boyer and
colleagues). Future studies are needed to explore
the effect of the length of exposure to each compo-
nent of the metabolic syndrome on cognition in
schizophrenia.
In our study, higher antipsychotic doses were
correlated with worse cognitive function. Studies
have reported contradictory ﬁndings concerning
the effects of antipsychotics on cognition in schizo-
phrenia. On the one hand, antipsychotics may
induce metabolic syndrome and its components,42,43
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but, on the other hand, antipsychotics have been
shown to be correlated with better cognitive func-
tioning in schizophrenia.44 Future studies are
needed to clarify the direct and indirect effects of
antipsychotics, through metabolic components, on
cognition.
This study had a number of limitations. First, the
sample size was relatively small. Second, the sam-
ple may not have been representative of the entire
population of patients with schizophrenia (eg, the
patients were mostly middle-aged). Third, this
study was limited by being cross-sectional rather
than prospective in design. Fourth, a number of
important data were not available, such as the
duration of hyperglycemia or hypertension, the
duration of treatment with antipsychotics, and
other moderating factors, such as the duration of
smoking and use of medications that may affect
cognition (eg, opioids, benzodiazepines, anti-
cholinergics, renin-angiotensin system blockers).
In conclusion, our ﬁndings suggest that certain
components of the metabolic syndrome, namely,
hypertension and hyperglycemia, may be linked to
cognitive functioning in patients with schizo-
phrenia. These results have some clinical implica-
tions. Several studies have found that treatment of
hypertension in other populations is associated
with cognitive improvement.39,45 After replication
with longitudinal approaches, these ﬁndings may
support complementary therapeutic approaches.
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